Insider · CIK 0001967669
Yong Ben
Files at CRBP (Corbus Pharmaceuticals Holdings, Inc.), BBOT (BridgeBio Oncology Therapeutics, Inc.). First filing Sep 15, 2026, latest Sep 15, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRBP: Corbus Pharmaceuticals Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Corbus Pharmaceuticals Holdings, Inc. | $16k 2,000 shares | -18% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | FTax withholding Common Stock | -1,047 | $3.94 | $4,125 | 43,529 | 7 d ago |
| Sep 14, 2026 | CRBP Corbus Pharmaceuticals Holdings, Inc. | SOpen-market sale Common Stock, par value $0.0001 per share10b5-1 | -2,000 | $7.84 | $16k | 9,383 | 27 d ago |
| Mar 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Common Stock | +46,670 | $0.00 | $0 | 46,670 | Mar 12, 2026 |
| Mar 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +210,000 | $0.00 | $0 | 210,000 | Mar 12, 2026 |
| Aug 26, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +357,177 | $0.00 | $0 | 357,177 | Aug 28, 2025 |
| May 30, 2025 | CRBP Corbus Pharmaceuticals Holdings, Inc. | AGrant or award Common Stock, par value $0.0001 per share | +4,800 | $0.00 | $0 | 7,583 | Jun 2, 2025 |
| May 30, 2025 | CRBP Corbus Pharmaceuticals Holdings, Inc. | AGrant or award Stock options (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.